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aampp and colleagues [1] state concerns about the budget im-
act analysis of palivizumab and that we do not take into ac-
ount the question of cost-effectiveness of respiratory syncytial
irus (RSV) prophylaxis. In reply, it should be noted that budget
mpact analyses are an established part of health care decision-
aking [2] and we provided references to published cost-effec-
iveness analyses. Although cost-effectiveness analyses ex-
mine worth of interventions, budget impact analyses examine
different economic dimension – the affordability of interven-
ions. We submit that both types of economic analyses are
aluable to consider, especially for therapies such as palivi-
umab, which is indicated for targeted populations at high
isk for serious RSV disease [3]. We indicate in our article that
key challenge in evaluating the cost-effectiveness of inter-
entions for pediatric populations is the accurate measure-
ent of health state utilities [4]. RSV illness affects not only
nfants; it also affects parents and the family unit [5]. Cost-
ffectiveness is largely influenced by the valuation of applica-
le pediatric health states.
Based on the 2006 Committee on Infectious Diseases of the
merican Academy of Pediatrics guidelines, infants born at
2–35 weeks gestation (wGA) and younger than 6 months at the
tart of the RSV season were recommended to receive prophy-
axis if they had two or more of five risk factors. Our analysis was
ot focused on the cost of therapy for infants already recom-
ended for immunoprophylaxis, but rather the incremental
ost of adding others not currently recommended by the AAP
uidelines, but at comparable risk. Hampp et al. [1] state that the
0%backgroundrateofRSVhospitalization inthemodel isanover-
stimate. As we document in our article, this information comes
rom a re-analysis of the pivotal randomized controlled trial of
alivizumab versus placebo and is different from the published ar-
icle [6] because the re-analysis excludes infants with chronic lung
isease (CLD). Palivizumab exhibited lower efficacy in infants with
LD compared with those without CLD (39% vs. 78% reduction in
SV hospitalization, respectively). There were few infants in the
ivotal trial that were 32–35 wGA and also had CLD. The risk reduc-
ion observed among preterm infants relevant to this analysis
32–35 wGA without CLD) is 82.2%. Because infants with CLD rou-
inely receive prophylaxis and prophylaxis of infants 32–35 wGA is
ontroversial, we believe it is important to model these groups sep-
rately. lHampp et al. [1] may also recognize that having several RSV
isk factors increases risk of RSV hospitalization in an additive or
ultiplicative fashion [7]. Infants born during the season are of
oung chronologic age (3 months) and, therefore, should be
ncluded in any economic evaluation. Because we are modeling
nfants 32–35 wGA that have young chronologic age and addi-
ional risk factors, we believe they are at much higher risk than
nfants more than 3 months old [8]. We submit that the higher
isk status of infants born during the season more than compen-
ates for shorter exposure. Having said that, we believe that
ore information on risk by birth month is needed and may
llow more accurate modeling. We did model lower rates of RSV
ospitalization in sensitivity analyses and found that the results
id not appreciably change.
Hampp et al. [1] assert that a drug with no clinical efficacy
nd a small population would also show a small budget im-
act; however, this is clearly not the case for palivizumab. The
eal-world effectiveness of using palivizumab to reduce RSV
ospitalizations was demonstrated in the Synagis Outcomes
egistry, which was conducted over 4 seasons and involved
9,548 patients [9]. In this prospective observational study,
nfants between 32–35 wGA who received prophylaxis were
ospitalized for RSV at a rate of 0.2% to 1.6%, which is similar
o the 1.8% rate seen in the clinical trial. Because our model
oes not incorporate rebates or discounts and assumes 100%
astage of unused vials, we do not believe that we are under-
stimating costs and actually may be overestimating costs.
e also model increases in prophylaxis costs in a sensitivity
nalysis, and these increases do not appreciably change the
ain findings because these infants comprise a small fraction
f a health plan.
Hampp et al. [1] state that we downplay the budget impact
nd that the money is better spent on other services. The spend-
ng on biologic therapies is depicted in Figure 2 of our article [4],
nd we believe it is appropriate to compare the investment in
SV prophylaxis with biologic spending in other therapeutic ar-
as. Furthermore, our society spends an estimated $3.5 billion an-
ually on medication errors [10] and $60 billion on Medicare fraud
11]. Efforts to reduce these mismanagement costs are likely to be
uccessful and open up resources for treatment and disease man-
gementwithinthehealthcaresystem, including immunoprophy-
axis of preterm infants against severe RSV illness.
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202 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 1 – 2 0 4In the absence of conclusive data indicating cost-effective-
ess of RSV prophylaxis, should we as a society deny high-risk
nfants an effective preventative therapy in the following setting
here 1) there is no RSV vaccine; 2) there are no effective RSV
reatments; and 3) the target population is both young in age and
mall in numbers? A budget impact model may be most infor-
ative when cost-effectiveness is inconclusive.
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ssues and failed to cite relevant articles on the analysis of
ncertainty in economic models.
The author failed to cite the work of Claxton et al. [2], who
tate that the choice of distribution for uncertain inputs
hould be guided by the form of the data, the type of parame-
er and the estimation process, and a discussion that details
he issue of reflecting uncertainty in economic models.
The author suggests that parametric bootstrapping is used
o propagate parameter uncertainty through an economic
odel whereas the most common approach is to use Monte
arlo simulation [2], although other approaches are availableThe author failed to distinguish adequately between epis-
emic and aleatory uncertainty. Epistemic uncertainty arises
rom a lack of knowledge and may be reduced or even elimi-
ated by obtaining more information, whereas aleatory un-
ertainty is due to randomness and is irreducible. The meth-
ds for estimating a confidence interval for an incremental
ost-effectiveness ratio described by the author are frequen-
ist methods for patient-level analyses and are not relevant to
discussion on the analysis of economic models.
It is questionable under what circumstance the “effect
ize” from an economic model will be presented using a rela-
ive risk (RR) because, in health economics, we are interested
n outcome measures that can be valued in the sense that K
